• Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug

    10 days ago - By Xconomy

    Unity Biotechnology is cutting nearly one third of its staff, a move that comes a month after the biotech's lead drug candidate failed a mid-stage study in osteoarthritis. South San Francisco-based Unity says that the corporate restructuring announced Tuesday should make the cash that it has left last through mid-2022, when data are expected for data the eye drug programs that are now the company's focus. According to Unity's second quarter financial report , the company had $39.6 million in cash and cash equivalents as of June 30. Unity develops treatments for diseases of aging, which the...
    Read more ...